Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Authors: Tremoulet AH; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA. Electronic address: atremoulet@ucsd.edu., Jain S; Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA., Jaggi P; Pediatrics, Nationwide Children's Hospital and Ohio State University, Columbus, OH, USA., Jimenez-Fernandez S; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA., Pancheri JM; Rady Children's Hospital San Diego, San Diego, CA, USA., Sun X; Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA., Kanegaye JT; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA., Kovalchin JP; Pediatrics, Nationwide Children's Hospital and Ohio State University, Columbus, OH, USA., Printz BF; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA., Ramilo O; Pediatrics, Nationwide Children's Hospital and Ohio State University, Columbus, OH, USA., Burns JC; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA.
Source: Lancet (London, England) [Lancet] 2014 May 17; Vol. 383 (9930), pp. 1731-8. Date of Electronic Publication: 2014 Feb 24.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(13)62298-9